DCTH
Delcath Systems, Inc.

Jennifer K Simpson, PhD., joined Sun BioPharma as President and Chief Executive Officer in July of 2020 and was also appointed as a Director at that time. She brings to the Company more than 12 years' experience in pharmaceutical executive leadership, global marketing and product commercialization. Most recently Dr. Simpson was the CEO of Delcath (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancer. From 2008 to 2012, Dr. Simpson served in various product leadership roles, including Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. (a wholly owned subsidiary of Eli Lilly and Company (NYSE:LLY)). From 2006 to 2008, Dr. Simpson held the position of Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a biotechnology company focused on innovative solutions in immunology, oncology and nephrology. Earlier in her career, Dr. Simpson spent over a decade as a hematology/oncology nurse practitioner and educator. She has served on the Board of Directors and Nominating and Corporate Governance Committee of Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) since 2019. Dr. Simpson earned a PhD. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.